Astellas Expected To Have To Raise Its Hostile Bid For OSI Of U.S.
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma's $3.5 billion offer for U.S.-based OSI Pharmaceuticals probably will have to be increased to be accepted by OSI, a major shareholder says